Posted by Michael Wonder on 10 Apr 2023
Cheaper medicines for graft versus host disease, chronic rhinosinusitis and oesophageal cancer
10 April 2023 - For the first time Jakavi (ruxolitinib) will be listed for the treatment of patients with either acute graft versus host disease (GVHD), or moderate to severe chronic GVHD who do not respond to, are dependent on, or intolerant of corticosteroids.
Nucala (mepolizumab) is being expanded to include PBS subsidy for the treatment of chronic rhinosinusitis with nasal polyps.
